Peter Ordentlich
Fondatore presso SYNDAX PHARMACEUTICALS, INC.
Patrimonio netto: 5 107 $ in data 31/05/2024
Profilo
Peter Ordentlich is the founder of Syndax Pharmaceuticals, Inc., which was founded in 2005.
He currently holds the title of Chief Scientific Officer at Syndax Pharmaceuticals, Inc. Dr. Ordentlich also held the position of Principal at The Salk Institute for Biological Studies and Research Scientist at X-Ceptor Therapeutics, Inc. In terms of education, Dr. Ordentlich obtained undergraduate and doctorate degrees from the University of Pennsylvania.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 15/02/2023 | 265 ( 0.00% ) | 5 107 $ | 31/05/2024 |
Posizioni attive di Peter Ordentlich
| Società | Posizione | Inizio |
|---|---|---|
| SYNDAX PHARMACEUTICALS, INC. | Fondatore | 11/10/2005 |
Precedenti posizioni note di Peter Ordentlich
| Società | Posizione | Fine |
|---|---|---|
X-Ceptor Therapeutics, Inc.
 X-Ceptor Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services X-Ceptor is a privately held biopharmaceutical company focusing on research in the rapidly developing field of orphan nuclear receptors that serve as the molecular targets for the discovery of novel small molecule pharmaceutical products for the treatment of human diseases. X-Ceptor has developed an integrated approach to drug discovery drawing from their in-house expertise in biology, chemistry and high-throughput screening. X-Ceptor's advantage lies in its understanding of orphan nuclear receptors and their signaling pathways, as well as its proprietary ability to employ these orphan nuclear receptors in transcriptional and biochemical based assays to discover novel therapeutic agents | Corporate Officer/Principal | - |
| The Salk Institute for Biological Studies | Corporate Officer/Principal | - |
Formazione di Peter Ordentlich
| University of Pennsylvania | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| SYNDAX PHARMACEUTICALS, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
X-Ceptor Therapeutics, Inc.
X-Ceptor Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services X-Ceptor is a privately held biopharmaceutical company focusing on research in the rapidly developing field of orphan nuclear receptors that serve as the molecular targets for the discovery of novel small molecule pharmaceutical products for the treatment of human diseases. X-Ceptor has developed an integrated approach to drug discovery drawing from their in-house expertise in biology, chemistry and high-throughput screening. X-Ceptor's advantage lies in its understanding of orphan nuclear receptors and their signaling pathways, as well as its proprietary ability to employ these orphan nuclear receptors in transcriptional and biochemical based assays to discover novel therapeutic agents | Commercial Services |
- Borsa valori
- Insiders
- Peter Ordentlich
